News
FDA Approves New Bladder Cancer Drug
The FDA declined an initial approval for the combination in May 2023.
The FDA declined an initial approval for the combination in May 2023.
A new trial assesses a screening intervention that aims to reduce unnecessary diagnoses of prostate cancer but still catch relevant cancers and...
Study examines whether immunotherapy has a role in the neoadjuvant setting before surgery.
Immunotherapy has expanded treatment options as an adjuvant and a first-line therapy in patients with renal cell carcinoma.
New data “suggest that meticulous follow-up is needed over a longer time” than previous studies have shown.
Many participants in a survey were unaware that further imaging or other types of tests could follow LDCT.
New research suggests that racial disparities in breast cancer are driven by more than socioeconomic factors.
Researchers use 16s rRNA sequencing to analyze stool samples from 94 patients with CRC.
Two and a half percent of breast cancer survivors developed a second primary breast cancer, a new study shows.
Researchers assess validity of the molecular targets and clinical benefits of genome-targeted cancer drugs approved in the United States from 2015...
NYU urologist discusses impact of a plant-based diet on heart health, prostate cancer, and sexual health.
Federal Practitioner welcomes submission of manuscripts on subjects pertinent to physicians, clinical pharmacists, physician...
Researchers evaluate new cfDNA blood-based test’s ability to detect CRC.
Immune checkpoint inhibitor combinations have restructured treatment guidelines for metastatic urothelial carcinoma.
To expedite approval of treatments for multiple myeloma, an FDA committee voted to support the use of MRD as an endpoint in clinical trials.
CanScan, MERCURY, and OncoSeek can detect a range of cancers and recognize the tissue of origin with high accuracy.
A test under development “looks very sensitive for detecting ovarian cancer early.”
Researchers ask 204 oncologists from 37 states for their views on the ethical implications of using AI for cancer care.
Across 15 studies, 41,709 adenomas were detected in 150,436 colonoscopies performed for any indication, resulting in a pooled overall ADR of 23.1...
Both CAR T-cell therapy and bispecific antibodies are helping patients with patients with R/R ALL live longer, but which treatment is better?
Researchers develop signature for pancreatic cancer based on microRNAs and cell-free DNA markers in the blood of patients with the disease.